Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

Crass, Ryan L; Pai, Manjunath P; Lodise, Thomas P

Crass, Ryan L; Pai, Manjunath P; Lodise, Thomas P.

Affiliation

Crass RL; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Pai MP; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Lodise TP; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.

J Antimicrob Chemother ; 74(1): 126-129, 2019 01 01.

Article in En | MEDLINE | ID: mdl-30252050

Subject(s)

Anti-Bacterial Agents/administration & dosage; Anti-Bacterial Agents/pharmacokinetics; Cystic Fibrosis/complications; Piperacillin, Tazobactam Drug Combination/administration & dosage; Piperacillin, Tazobactam Drug Combination/pharmacokinetics; Tobramycin/administration & dosage; Tobramycin/pharmacokinetics; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections/drug therapy; Female; Humans; Male; Middle Aged; Prospective Studies; Young Adult; beta-Lactamase Inhibitors/administration & dosage; beta-Lactamase Inhibitors/pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Tobramycin / Cystic Fibrosis / Piperacillin, Tazobactam Drug Combination / Anti-Bacterial Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google